AVCN.TO实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 03:59):

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide...

Stats
今日成交量	156 000
平均成交量	113 572
市值	30.69M
EPS	$0 ( 2024-04-01 )
下一个收益日期	( $0 ) 2024-05-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.06
ATR14	$0.00100 (0.29%)

音量相关性

長: -0.48 (neutral)

短: 0.00 (neutral)

Signal:(51.949) Neutral

AVICANNA INC 相关性

10 最正相关
SJR-B.TO	0.846
HGRO.TO	0.846
CEU.TO	0.845
SSF-UN.TO	0.841
MDA.TO	0.841
NVCN.TO	0.834
OLY.TO	0.827
PFMN.TO	0.827
HSAV.TO	0.82
LAM.TO	0.81

10 最负相关
SOY.TO	-0.908
IMV.TO	-0.868
PET.TO	-0.863
QSR.TO	-0.861
IMP.TO	-0.853
HUT.TO	-0.833
AII.TO	-0.83
EXE.TO	-0.828
CGY.TO	-0.825
HLF.TO	-0.824

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

AVICANNA INC 相关性 - 货币/商品

0.00
( neutral )

AVICANNA INC 财务报表

Annual	2023
营收:	$16.79M
毛利润:	$6.58M (39.20 %)
EPS:	$-0.0931

FY	2023
营收:	$16.79M
毛利润:	$6.58M (39.20 %)
EPS:	$-0.0931

FY	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$0

FY	2022
营收:	$4.05M
毛利润:	$1.12M (27.55 %)
EPS:	$-0.290

Financial Reports:

No articles found.

AVICANNA INC

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.